多重耐药鲍曼不动杆菌感染替加环素治疗进展  

Progress in Treatment of Tigecycline with Multidrug Resistant Acinetobacter Baumanni

作　　者：薄林会[1] BO Lin-hui(Infection Department,Tianjin Baodi District People's Hospital,Tianjin 301800,China)

机构地区：[1]天津市宝坻区人民医院感染科,天津301800

出　　处：《药品评价》2020年第5期48-50,共3页Drug Evaluation

摘　　要：目的:探讨多重耐药鲍曼不动杆菌感染替加环素治疗进展。方法:回顾性收集我院2018年12月至2019年12月收治的多重耐药鲍曼不动杆菌感染患者58例临床资料,依据治疗方法将其分为观察组(替加环素治疗,30例),对照组(孢哌酮舒巴坦治疗,28例)。比较两组治疗效果、降钙素原(PCT)、C-反应蛋白(CRP)、白细胞计数(WBC),并记录28d存活率、新发器官衰竭率、微生物清除率及不良反应。结果:观察组治疗总有效率为83.33%,高于对照组的57.14%,差异有统计学意义(P<0.05);两组微生物清除率对比,差异无统计学意义(P>0.05);相较于对照组,观察组28d存活率较高,新发器官衰竭率较低,差异有统计学意义(P<0.05);治疗2周后,相较于对照组,观察组PCT、CRP及WBC均降低,且治疗前后对比,差异有统计学意义(P<0.05);观察组不良反应发生率为3.33%,略低于对照组的7.14%,但差异无统计学意义(P>0.05)。结论:多重耐药鲍曼不动杆菌感染替加环素治疗效果较好,具有较高的安全性及可靠性。Objective:To investigate the progress of tigecycline treatment in multi-drug resistant Acinetobacter baumannii infection.Methods:The clinical data of 58 patients with multidrug resistant Acinetobacter baumannii infection treated in our hospital from December 2018 to December 2019 were retrospectively collected and divided into observation group(tegacycline treatment,30 cases)and control group(cefoperazone sulbactam treatment,28 cases)according to the treatment method.the therapeutic effects,procalcitonin(PCT),C-reactive protein(CRP),white blood cell count(WBC)were compared between the two groups,and 28d survival rate,new organ failure rate,microbial clearance rate and adverse reactions were recorded.Results:The total effective rate in the observation group was 83.33%,compared with 57.14%in the control group(P<0.05),the difference was not significant(P>0.05),the survival rate of 28d in the observation group was higher,the rate of new organ failure was lower(P<0.05).The incidence of adverse reactions in the observation group was 3.33%,slightly lower than that in the observation group,but the difference was not statistically significant(P>0.05).Conclusion:Tigecycline is effective and safe in the treatment of multidrug-resistant Acinetobacter baumannii infection.

关 键 词：感染 多重耐药鲍曼不动杆菌 替加环素 新发器官衰竭率 微生物清除率 

分 类 号：R978.1[医药卫生—药品]